A Phase II Study of Nilotinib in Pediatric Patients with CML: Long-Term Update on Growth Retardation and Safety

This Phase II open-label study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) met its coprimary end points, showing sustained nilotinib efficacy in patients with newly diagnosed or imatinib/dasatinib resistant/intolerant CML.